Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP

Abstract

AML1/Evi-1 is a chimeric protein that is derived from t(3;21), found in blastic transformation of chronic myelogenous leukemia. It is composed of the N-terminal AML1 portion with the DNA-binding Runt domain and the C-terminal Evi-1 portion. It has been shown to dominantly repress AML1-induced transactivation. The mechanism for it has been mainly attributed to competition with AML1 for the DNA-binding and for the interaction with PEBP2β (CBFβ), a partner protein which heterodimerizes with AML1. It was recently found that Evi-1 interacts with C-terminal binding protein (CtBP) to repress TGFβ-induced transactivation. Here, we demonstrate that AML1/Evi-1 interacts with CtBP in SKH1 cells, a leukemic cell line which endogenously overexpresses AML1/Evi-1 and that AML1/Evi-1 requires the interaction with CtBP to repress AML1-induced transactivation. The association with CtBP is also required when AML1/Evi-1 blocks myeloid differentiation of 32Dcl3 cells induced by granulocyte colony-stimulating factor. Taken together, it is suggested that one of the mechanisms for AML1/Evi-1-associated leukemogenesis should be an aberrant recruitment of a corepressor complex by the chimeric protein.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Boyd JM, Subramanian T, Schaeper U, La Regina M, Bayley S, Chinnadurai G . 1993 EMBO J. 12: 469–478

  • Brannon M, Brown JD, Bates R, Kimelman D, Moon RT . 1999 Development 126: 3159–3170

  • Burke LJ, Baniahmad A . 2000 FASEB J. 14: 1876–1888

  • Criqui-Filipe P, Ducret C, Maira SM, Wasylyk B . 1999 EMBO J. 18: 3392–3403

  • Cuenco GM, Nucifora G, Ren R . 2000 Proc. Natl. Acad. Sci. USA 97: 1760–1765

  • Dressel U, Bailey PJ, Wang SC, Downes M, Evans RM, Muscat GE . 2001 J. Biol. Chem. 276: 17007–17013

  • Fenrick R, Amann JM, Lutterbach B, Wang L, Westendorf JJ, Downing JR, Hiebert SW . 1999 Mol. Cell. Biol. 19: 6566–6574

  • Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, Mancini M, Pelicci PG, Lo Coco F, Nervi C . 2001 Cancer Res. 61: 2–7

  • Fixe P, Praloran V . 1998 Cytokine 10: 32–37

  • Fox AH, Liew C, Holmes M, Kowalski K, Mackay J, Crossley M . 1999 EMBO J. 18: 2812–2822

  • Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG . 1995 Proc. Natl. Acad. Sci. USA 92: 4917–4921

  • Guidez F, Petrie K, Ford AM, Lu H, Bennett CA, MacGregor A, Hannemann J, Ito Y, Ghysdael J, Greaves M, Wiedemann LM, Zelent A . 2000 Blood 96: 2557–2561

  • Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE . 1997 Cell 89: 341–347

  • Hirai H . 1999 Int. J. Biochem. Cell. Biol. 31: 1367–1371

  • Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Takeuchi K, Maki K, Ogawa S, Chiba S, Mitani K, Hirai H . 2000 Blood 96: 3154–3160

  • Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolffe AP, Ge H . 1997 Curr. Biol. 7: 689–692

  • Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H . 2001 Blood 97: 2815–2822

  • Jin S, Scotto KW . 1998 Mol. Cell. Biol. 18: 4377–4384

  • Katsanis N, Fisher EM . 1998 Genomics 47: 294–299

  • Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D . 2001 Curr. Opin. Genet. Dev. 11: 162–166

  • Kitabayashi I, Yokoyama A, Shimizu K, Ohki M . 1998 EMBO J. 17: 2994–3004

  • Kosugi H, Towatari M, Hatano S, Kitamura K, Kiyoi H, Kinoshita T, Tanimoto M, Murate T, Kawashima K, Saito H, Naoe T . 1999 Leukemia 13: 1316–1324

  • Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H . 1998a Blood 92: 4003–4012

  • Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H . 1998b Nature 394: 92–96

  • Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, Ogawa S, Moriguchi T, Nishida E, Yazaki Y, Hirai H . 2000 EMBO J. 19: 2958–2968

  • Kurokawa M, Ogawa S, Tanaka T, Mitani K, Yazaki Y, Witte ON, Hirai H . 1995 Oncogene 11: 833–840

  • Look AT . 1997 Science 278: 1059–1064

  • Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW . 1998 Mol. Cell. Biol. 18: 7176–7184

  • Marks PA, Richon VM, Rifkind RA . 2000 J. Natl. Cancer Inst. 92: 1210–1216

  • Minucci S, Nervi C, Lo Coco F, Pelicci PG . 2001 Oncogene 20: 3110–3115

  • Mitani K . 1997 Leukemia 11: 294–296

  • Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H, Yazaki Y, Ohki M, Hirai H . 1994 EMBO J. 13: 504–510

  • Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y, Kamada N, Ohki M . 1993 EMBO J 2715–2721

  • Miyoshi H, Ohira M, Shimizu K, Mitani K, Hirai H, Imai T, Yokoyama K, Soeda E, Ohki M . 1995 Nucleic Acids Res. 23: 2762–2769

  • Miyoshi H, Shimizu K, Kozu T, Maseki N, Keneko Y, Ohki M . 1991 Proc. Natl. Acad. Sci. USA 88: 10431–10434

  • Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM . 1997 Cell 89: 373–380

  • Niwa H, Yamamura K, Miyazaki J . 1991 Gene 108: 193–199

  • Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR . 1996 Cell 84: 321–330

  • Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T, Suzushima H, Takatsuki K, Kanno T, Shigesada K, Ito Y . 1999 Blood 93: 1817–1824

  • Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, Loh M, Felix C, Roy DC, Busque L, Kurnit D, Willman C, Gewirtz AM, Speck NA, Bushweller JH, Li FP, Gardiner K, Poncz M, Maris JM, Gilliland DG . 1999 Nat. Genet. 23: 166–175

  • Sowa Y, Orita T, Hiranabe-Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T . 1999 Ann. NY Acad. Sci. 886: 195–199

  • Sundqvist A, Sollerbrant K, Svensson C . 1998 FEBS Lett. 429: 183–188

  • Takebe Y, Seiki M, Fujisawa J, Hoy P, Yokota K, Arai K, Yoshida M, Arai N . 1988 Mol. Cell. Biol. 8: 466–472

  • Tanaka K, Tanaka T, Kurokawa M, Imai Y, Ogawa S, Mitani K, Yazaki Y, Hirai H . 1998 Blood 91: 1688–1699

  • Tanaka T, Mitani K, Kurokawa M, Ogawa S, Tanaka K, Nishida J, Yazaki Y, Shibata Y, Hirai H . 1995a Mol. Cell. Biol. 15: 2383–2392

  • Tanaka T, Nishida J, Mitani K, Ogawa S, Yazaki Y, Hirai H . 1994 J. Biol. Chem. 269: 24020–24026

  • Tanaka T, Tanaka K, Ogawa S, Kurokawa M, Mitani K, Nishida J, Shibata Y, Yazaki Y, Hirai H . 1995b EMBO J. 14: 341–350

  • Turner J, Crossley M . 1998 EMBO J. 17: 5129–5140

  • Turner J, Crossley M . 2001 Bioessays 23: 683–690

  • Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM . 1998 Proc. Natl. Acad. Sci. USA 95: 10860–10865

  • Wang J, Saunthararajah Y, Redner RL, Liu JM . 1999 Cancer Res. 59: 2766–2769

  • Westendorf JJ, Hiebert SW . 1999 J. Cell. Biochem. Suppl 51–58

  • Wheeler JC, Shigesada K, Gergen JP, Ito Y . 2000 Semin. Cell. Dev. Biol. 11: 369–375

  • Zent C, Kim N, Hiebert S, Zhang DE, Tenen DG, Rowley JD, Nucifora G . 1996 Curr. Top. Microbiol. Immunol. 211: 243–252

  • Zhang CL, McKinsey TA, Lu JR, Olson EN . 2001 J. Biol. Chem. 276: 35–39

  • Zhang DE, Hetherington CJ, Chen HM, Tenen DG . 1994 Mol. Cell. Biol. 14: 373–381

  • Zhang DE, Hetherington CJ, Meyers S, Rhoades KL, Larson CJ, Chen HM, Hiebert SW, Tenen DG . 1996 Mol. Cell. Biol. 16: 1231–1240

  • Zhang Y, Iratni R, Erdjument-Bromage H, Tempst P, Reinberg D . 1997 Cell 89: 357–364

Download references

Acknowledgements

We thank M Ohki (National Cancer Center Research Institute, Tokyo, Japan) for providing AML1, Y Ito (Institute for Virus Research, Kyoto University, Japan) for PEBP2β, DE Zhang (The Scripps Research Institute, La Jolla, CA, USA) for pM-CSF-R-luc, SL McKnight (Johns Hopkins University, Baltimore, MD, USA) for C/EBPα, SL Schreiber (Harvard University, Cambridge, MA, USA) for Flag-HDAc1, G Chinnadurai (St. Louis University, MO, USA) for T7-hCtBP1, K Arai (The Institute of Medical Science, University of Tokyo, Japan) for pME18S, and J Miyazaki (Osaka University, Japan) for pCXN2. The murine IL-3 is a generous gift from Kirin Brewery (Tokyo, Japan). This study is supported in part by Grants-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare and from the ministry of Education, Culture, Sports, Science and Technology of Japan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hisamaru Hirai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Izutsu, K., Kurokawa, M., Imai, Y. et al. The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP. Oncogene 21, 2695–2703 (2002). https://doi.org/10.1038/sj.onc.1205356

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205356

Keywords

This article is cited by

Search

Quick links